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Cholesteryl Ester Transfer Protein Decreases High-Density
Lipoprotein and Severely Aggravates Atherosclerosis in
APOE*3-Leiden Mice
Marit Westerterp, Caroline C. van der Hoogt, Willeke de Haan, Erik H. Offerman,
Geesje M. Dallinga-Thie, J. Wouter Jukema, Louis M. Havekes, Patrick C.N. Rensen
Objective—The role of cholesteryl ester transfer protein (CETP) in the development of atherosclerosis is still undergoing
debate. Therefore, we evaluated the effect of human CETP expression on atherosclerosis in APOE*3-Leiden (E3L) mice
with a humanized lipoprotein profile.
Methods and Results—E3L mice were crossbred with human CETP transgenic mice. On a chow diet, CETP expression
increased plasma total cholesterol (TC) (43%; P0.05). To evaluate the effects of CETP on the development of
atherosclerosis, mice were fed a Western-type diet containing 0.25% cholesterol, leading to 4.3-fold elevated TC levels
in both E3L and CETP.E3L mice (P0.01). On both diets, CETP expression shifted the distribution of cholesterol from
high-density lipoprotein (HDL) toward very-low-density lipoprotein (VLDL)/low-density lipoprotein (LDL). Moreover,
plasma of CETP.E3L mice had reduced capacity (39%; P0.05) to induce SR-BI–mediated cholesterol efflux from
Fu5AH cells than plasma of E3L mice. After 19 weeks on the Western-type diet, CETP.E3L mice showed a 7.0-fold
increased atherosclerotic lesion area in the aortic root compared with E3L mice (P0.0001).
Conclusions—CETP expression in E3L mice shifts the distribution of cholesterol from HDL to VLDL/LDL, reduces
plasma-mediated SR-BI–dependent cholesterol efflux, and represents a clear pro-atherogenic factor in E3L mice. We
anticipate that the CETP.E3L mouse will be a valuable model for the preclinical evaluation of HDL-raising interventions
on atherosclerosis development. (Arterioscler Thromb Vasc Biol. 2006;26:2552-2559.)
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Cardiovascular disease (CVD) is the leading cause ofdeath in the Western world and its prevalence is increas-
ing in Eastern Europe and developing countries.1 The main
cause of CVD is atherosclerosis, characterized by the com-
bination of chronic inflammation and/or hyperlipidemia.1
Both low high-density lipoprotein (HDL) cholesterol plasma
levels and high very-low-density lipoprotein (VLDL)/low-
density lipoprotein (LDL) cholesterol levels are independent
risk factors for atherosclerosis development.2 The ratio of
VLDL/LDL to HDL is to a great extent affected by the
cholesteryl ester transfer protein (CETP).3
CETP is a transfer factor that mediates the exchange of
cholesteryl esters (CE) and triglycerides (TG) between the
apoB-containing lipoproteins (ie, chylomicrons, VLDL, and
LDL) and HDL in plasma.3 As such, CETP may be anti-
atherogenic by facilitating reverse cholesterol transport
(RCT) from peripheral tissues to the liver via the VLDL/LDL
pathway. Another potential role of CETP in RCT has recently
been supported by the observation that CETP mediates
HDL-CE uptake by hepatocytes independently of SR-BI and
the LDL receptor (LDLr) in vitro.4 However, CETP may be
pro-atherogenic by enhancing the levels of VLDL/LDL with
concomitant reduction of anti-atherogenic HDL levels.
Many studies in humans have been performed regarding
the association between CETP and lipoprotein levels and the
subsequent development of CVD.5–9 For example, CETP
deficiency that was observed in a Japanese population in-
creased CVD despite increased HDL levels.8,9 In contrast,
high CETP concentrations are associated with a faster ath-
erosclerosis progression in men with proven CVD.6 This
finding is corroborated by a correlation study in humans,
which showed that the Taq1B polymorphism in CETP is
associated with increased plasma CETP, decreased plasma
HDL, and an increased progression of CVD.7 However, this
might be confined to hypertriglyceridemic subjects as it has
been shown in the prospective EPIC-Norfolk study that
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CETP correlated positively with future CVD risk only in
humans with high TG levels (1.7 mmol/L).5
Because the studies in humans have been associative and
the effects of CETP expression on lipid metabolism and
atherosclerosis gave conflicting results, the role of CETP has
been addressed in mice that are naturally deficient for
CETP.10 To evaluate the direct effect of CETP on atheroscle-
rosis development, CETP transgenic mouse models have
been generated11 and crossbred on different genetic back-
grounds. CETP expression was found to be anti-atherogenic
in APOC3 and lecithin:cholesterol acyltransferase (LCAT)
transgenic mice.12,13 However, these mouse models may not
be the preferred models for atherosclerosis studies because
APOC3 and LCAT mice develop only very small atheroscle-
rotic lesions.12,13
In contrast to APOC3 and LCAT mice, CETP was shown to
be pro-atherogenic in apoe/ and ldlr/ mice.14 Because
those mice exhibit both nearly complete blockage of the
clearance of VLDL/LDL particles by the liver, it has been
hypothesized that the cholesterol-rich particles that are
formed as a result of CETP expression accumulate in the
vessel wall of these mice.14 However, the suitability of these
particular mouse models for evaluating the effect of CETP on
atherosclerosis development may be limited as the potential
effect of CETP in the facilitation of reverse cholesterol
transport (RCT) from peripheral tissues to the liver via the
VLDL/LDL pathway is expected to be largely reduced by
apoE or LDLr deficiency. Furthermore, expression of CETP
in apoe/ mice resulted in unnaturally elevated TG levels.14
Finally, the CETP.APOB mouse has lipoprotein profiles on a
chow diet comparable to normolipidemic humans,15 but does
not develop atherosclerosis unless treated with a cholesterol-
rich diet containing cholate,16 that, next to facilitating cho-
lesterol absorption, induces chronic inflammation.17
In the present study, we crossbred the human CETP
transgenic mouse11 with the APOE*3-Leiden (E3L) mouse.18
The E3L mouse expresses a mutation of the human APOE3
gene resulting in a slightly attenuated clearance of apoB-
containing particles via the LDLr pathway.19 As a result,
cholesterol and TG levels are only moderately increased on a
chow diet.19 On a Western-type diet containing 0.25% cho-
lesterol, these mice exhibit a more humanized lipoprotein
cholesterol distribution.20 Its VLDL cholesterol levels are
highly susceptible to cholesterol levels in the diet, whereas
VLDL–TG levels decline to a normotriglyceridemic human
level.20 In the present study, we thus aimed to investigate the




Human CETP transgenic mice expressing the human CETP gene
under control of its natural flanking regions (strain 5203, heterozy-
gous expression of CETP),11 were obtained from Jackson Laborato-
ries (Bar Harbor, Me), and were crossbred with E3L mice,18 of which
female mice were used for experiments. CETP.E3L and E3L mice
were housed under standard conditions with a 12-hour light cycle
(7:00 AM to 7:00 PM) and were fed ad libitum with regular chow.
Blood samples were collected by tail vein bleeding 1 week before
feeding the mice a Western-type diet (semi-synthetic cholesterol-rich
diet, containing 15% [w/w] fat and 0.25% [w/w] cholesterol) (Diet
W; Hope Farms, Woerden, The Netherlands) and every 4 weeks
thereafter. Hereto, mice were fasted for 4 hours with food withdrawal
at 9:00 AM as described previously.21 The experiments were ap-
proved by the institutional Ethical Committee on Animal Care and
Experimentation.
Lipid and Lipoprotein Analysis
Plasma TC and TG levels were determined using enzymatic kits
236691 and 11488872 (Roche Molecular Biochemicals, Indianapo-
lis, Ind), respectively. For determination of the lipid distribution over
plasma lipoproteins by fast performance liquid chromatography, 50
L of pooled plasma from 11 mice per group was injected onto a
Superose 6 HR 10/30 column (A´ kta System; Amersham Pharmacia
Biotech, Piscataway, NJ) and eluted at a constant flow rate of 50
L/min phosphate-buffered saline (PBS), 1 mmol/L EDTA (Sigma),
pH 7.4. Fractions of 50 L were collected and assayed for TC and
TG using enzymatic assays (Roche Molecular Biochemicals). For
the analysis of the apolipoprotein distribution, fractions of 50 L
were diluted 1:1 (v/v) in sample buffer (0.125 mol/L Tris, pH 6.8;
4% [wt/vol]) SDS, 20% [wt/vol] glycerol; 10% [v/v]
-mercaptoethanol; 0.01% [wt/vol] bromophenol blue). Samples
were then applied onto a 4% to 20% Tris Glycine precast polyacryl-
amide minigel (Gradipore Ltd, French Forest, Australia). Electro-
phoresis was performed according to manufacturer’s instructions.
Protein bands were stained with Coomassie Brilliant Blue R250
(Sigma), and apparent molecular masses were identified.
CETP Activity and Protein Levels
CETP activity in plasma was measured as the transfer of [3H]cho-
lesteryl oleate ([3H]CO) from exogenous LDL to HDL as described
elsewhere.22 Hereto, 2.5 L of plasma of animals on chow and 0.5
L of plasma of animals on the Western-type diet was added as a
CETP source, with and without a preceding precipitation of apoB-
containing particles using sodium phosphotungstate in the presence
of magnesium chloride.23 CETP activity was calculated as mol CE
transfer per mL plasma per hour. Plasma CETP mass was analyzed
as described previously.24 In short, a 2-antibody sandwich immuno-
assay with a combination of the monoclonal antibodies TP1 and TP2




Plasma apoAI concentrations were determined using a sandwich
enzyme-linked immunosorbent assay (ELISA). Hereto, goat–anti-
mouse apoAI polyclonal antibody (ab7614; Abcam plc, Cambridge,
UK; dilution 1:1000) was coated overnight onto Costar strips
(Costar, Inc, New York, NY) (1 g/mL) at 4°C and incubated with
diluted mouse plasma (dilution 1:40400) for 2 hours at room
temperature. Subsequently, rabbit–anti-mouse apoAI antibody
(ab20453; Abcam; dilution 1:2000) was added and incubated for 1
hour at RT. Finally, horseradish peroxidase (HRP)-conjugated
swine–anti-rabbit IgG antibody (SWARPO; dilution 1:2000) was
added and incubated for 1 hour at RT. HRP was detected by
incubation with tetramethylbenzidine (Organon Teknika, Boxtel,
The Netherlands) for 15 minutes at room temperature. Purified
mouse apoAI (A23100m; Biodesign International, Saco, Me) was
used as a standard.
Cholesterol Efflux
The effect of macrophage CETP on lipid accumulation and choles-
terol efflux was investigated using thioglycollate-elicited peritoneal
macrophages from E3L and CETP.E3L mice. Macrophages were
loaded with acetylated LDL (AcLDL) (50 g/mL) and [3H]choles-
terol (2 Ci/mL) for 48 hours and subsequently half of the cells was
lysed to determine the [3H]cholesterol association related to cell
protein.25 Cholesterol efflux for a period of 10 hours was assessed in
the remainder of those cells, with and without human HDL (50
g/mL) as a cholesterol acceptor.
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The capacity of the plasma from mice fed the Western-type diet to
induce ABCA1 dependent cholesterol efflux was determined using
J774 murine macrophage-like cells. To induce cholesterol loading,
J774 cells were incubated with AcLDL (50 g/mL) and [3H]choles-
terol (2 Ci/mL) for 48 hours. Subsequently, cells were incubated
without and with 0.3 mmol/L 8-(4-chlorophenyl thio)adenosine
3:5-cyclic monophosphate (cAMP analogue; Sigma) for 16 hours
to induce ABCA1 expression. Then, J774 macrophages were incu-
bated for 4 hours in the absence or presence of 1% of a plasma pool
of 10 mice each. Human apoAI (10 g/mL) and HDL (50 g/mL)
served as positive controls. The cAMP-dependent cholesterol efflux
from J774 cells was considered the ABCA1-mediated efflux.26
The capacity of the plasma from mice fed the Western-type diet to
induce SR-BI dependent cholesterol efflux was determined using
Fu5AH rat hepatoma cells (generous gift from Dr N. Fournier,
Chatenay-Malabry, France). First, cells were loaded with cholesterol
(30 g/mL) in the presence of [3H]cholesterol (2 Ci/mL) for 24
hours. Then, cholesterol laden Fu5AH cells were incubated for 4
hours in the absence or presence of 1% of a plasma pool of 10 mice
each. Human apoAI (10 g/mL) and HDL (50 g/mL) served as
positive controls. Cholesterol efflux was interpreted as the SR-BI–
mediated efflux.27
Atherosclerosis Study and Atherosclerotic
Lesion Analysis
At 8 weeks of age, CETP.E3L and E3L littermates were fed the
Western-type diet. Mice were euthanized after 19 weeks of diet.
Hearts were isolated and fixed in phosphate-buffered 4% formalde-
hyde, dehydrated and embedded in paraffin, and were cross-
sectioned (5 m) throughout the entire aortic root area. Per mouse,
4 sections with 40-m intervals were used for quantification of
atherosclerotic lesion area and characterization of lesion severity.
Sections were routinely stained with hematoxylin-phloxine-saffron
(HPS). Lesion area was determined using Leica Qwin image analysis
software (EIS, Asbury, NJ). Atherosclerotic lesions were also cate-
gorized for severity, according to the American Heart System for
humans,28 which we have adapted to categorize lesions in mice.29
Three types of categories were discerned: (1) no lesions (type 0); (2)
early lesions were fatty streaks containing only foam cells (type 1 to
3); and (3) advanced lesions showing foam cells in the media and
presence of fibrosis, cholesterol clefts, mineralization, and/or necro-
sis (type 4 to 5). The number observed in each category is expressed
as a percentage of the total number of lesions present within one
group of mice (CETP.E3L or E3L control group).
Statistical Analysis
All data are presented as meansSD. Statistical differences were
assessed using the Mann-Whitney U test for all experiments, except
for the typing of the atherosclerotic lesions, in which statistical
differences were determined using the 2 test. P0.05 was regarded
as statistically significant.
Results
Effect of CETP Expression on Lipids and
Lipoprotein Profiles on a Chow Diet and a
Western-Type Diet
The effect of CETP expression on plasma parameters in E3L
mice on a chow and a Western type diet are summarized in
the Table. On a chow diet, CETP expression resulted in a
CETP concentration of 6.23.3 g/mL and activity of
0.250.05 mol CE/mL per hour as measured in whole
plasma. This CETP concentration is 3-fold higher than
found in normolipidemic humans (ie, 1.80.6 g/mL).30
Precipitation of apoB-containing lipoproteins before determi-
nation of CETP concentration and activity did not affect these
values (results not shown), indicating that plasma CETP
resided specifically on HDL. CETP expression increased
plasma TC levels (43%; P0.05), and tended to increase
plasma TG levels (23%).
As compared with the chow diet, the Western-type diet
increased TC levels 4.3-fold (P0.001), whereas TG levels
decreased 60% (P0.01), in both mouse groups (Table).
Such a decrease in TG has been found consistently on feeding
E3L mouse a Western-type diet,20,31,32 although the mecha-
nism has not been elucidated yet. In CETP.E3L mice, the
Western-type diet increased the plasma CETP concentration
11.7-fold (P0.001) (Table), with a concomitant increase in
plasma CETP activity of 4.4-fold (P0.05). This led to
increased TC levels (43%; P0.01) and a tendency to
increased TG levels (26%) in CETP.E3L as compared with
E3L mice (Table).
Lipoprotein fractionation showed that CETP increased
cholesterol in VLDL 2-fold and decreased cholesterol in
regularly sized HDL (fractions 17 to 22) by 25% (Figure
1A). Likewise, the plasma apoAI content was reduced by
25% (P0.05) (Figure 1D). In addition, the lipoprotein
particle eluting in fractions 14 to 16 in E3L mice almost
disappeared on CETP expression (Figure 1A). This particle
was rich in apoE and did not contain apoAI (Figure 1B, 1C),
and thus represented large apoE-rich HDL-1, consistent with
previous observations.19 Therefore, CETP expression reduced
the cholesterol content in total HDL 2-fold.
Effect of CETP Expression in E3L Macrophages
on Cholesterol Uptake and Cholesterol Efflux
To investigate whether macrophage-associated CETP affects
the uptake of cholesterol, peritoneal macrophages were iso-
lated from E3L and CETP.E3L mice and incubated with
AcLDL and [3H]cholesterol. Macrophages from CETP.E3L
mice showed no different cholesterol uptake as compared
with those from E3L mice (Figure 2A). Also, CETP expres-
sion did not affect cholesterol efflux from macrophages using
HDL as a cholesterol acceptor (Figure 2B). Taken together,
CETP expression in macrophages did not affect either the
uptake or efflux of cholesterol.
Plasma Parameters in E3L and CETP.E3L Mice Fed a Chow Diet











E3L ND ND 3.71.2 3.51.1
CETP.E3L 6.23.3 0.250.05 5.32.3* 4.30.6
Western-type diet
E3L ND ND 165 1.40.5
CETP.E3L 72.88.7 1.10.5 236† 1.91.1
Plasma was obtained from 7-week-old 4-hour-fasted E3L (n10) and
CETP.E3L (n9) mice on a chow diet, or from 4-hour-fasted E3L (n13) and
CETP.E3L (n15) mice fed a Western-type diet for 19 weeks. Plasma CETP
protein, CETP activity, and TC and TG levels were determined and are
represented as meansSD.
*†Significant differences as compared with E3L mice. *P0.05, †P0.01.
ND indicates not detectable.
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Effect of CETP Expression on the
Cholesterol-Accepting Capacity of Plasma
We determined the effect of plasma from E3L and CETP.E3L mice
on cellular cholesterol efflux, either from cholesterol-laden cAMP
analogue-treated J774 cells (representing ABCA1-mediated efflux)26
or from Fu5AH cells (representing SR-BI-mediated efflux).27
Cholesterol efflux from J774 cells was largely induced in the
presence of apoAI, whereas HDL had no effect, which is consistent
with ABCA1-mediated efflux (Figure 2C). The ABCA1-dependent
cholesterol accepting potencies of plasma of E3L and CETP.E3L
mice were similar (12%). Cholesterol efflux from Fu5AH cells
was hardly induced on incubation with apoAI, yet largely induced on
incubation with HDL, consistent with SR-BI–mediated efflux (Fig-
ure 2D). Plasma of CETP.E3L mice was 39% (P0.05) less efficient
in inducing SR-BI–mediated cholesterol efflux as compared with
plasma of E3L mice (Figure 3D). Taken together, CETP expression
reduced the potency of plasma to mediate SR-BI–dependent choles-
terol efflux, without compromising the ABCA1-mediated cholesterol
efflux.
Effect of CETP Expression on
Atherosclerosis Development
To investigate the effect of CETP on atherosclerosis devel-
opment, mice were fed the Western-type diet from 8 weeks of
age. In E3L mice, plasma cholesterol levels raised up to
16 mmol/L and in CETP.E3L mice to 23 mmol/L, which
remained stable throughout the whole study (supplemental
Figure I, available online at http://atvb.ahajournals.org). After
19 weeks of the Western-type diet, the development of
atherosclerosis in E3L mice was still in the early phase
because a lot of segments were either unaffected (type 0) or
contained foam cell-rich lesions (type 1 to 3) (Figure 3A, 3B).
In contrast, CETP.E3L mice developed much more advanced
lesions that affected the integrity of the media, contained
cholesterol clefts, and showed calcification (type 4 to 5)
(Figure 3A, 3B). The much more advanced atherosclerosis in
CETP.E3L mice was reflected in a 7.0-fold increase in
atherosclerotic lesion area (Figure 3C). Collectively, CETP
represents a clear pro-atherogenic factor in E3L mice.
Discussion
The role of CETP in atherosclerosis is still undergoing
debate.5–9,12–14 In the present study, the effect of CETP
expression on atherosclerosis development was evaluated in
E3L mice, a mouse model with a more humanized cholesterol
distribution over lipoproteins. We found that CETP expres-
Figure 1. Effect of CETP on cholesterol distribution among
lipoproteins in E3L mice fed a Western-type diet containing
0.25% cholesterol. Plasma from 4-hour-fasted E3L (white sym-
bols) and CETP.E3L mice (black symbols) fed a Western-type
diet containing 0.25% cholesterol for 19 weeks was pooled per
genotype (n11 per pool). Lipoproteins were size-fractionated
by fast performance liquid chromatography on a Superose 6
column, and the individual fractions were assayed for TC (A).
Lipoprotein fractions 14 to 19 were assayed for protein and
apparent molecular masses were identified representing apoAI
and apoE in female E3L (B) and CETP.E3L (C) mice. Total apoAI
levels were determined using a sandwich ELISA (D).
Figure 2. Effect of CETP expression on cholesterol association
and cholesterol efflux. Peritoneal macrophages were isolated
from E3L (white symbols) and CETP.E3L (black symbols). Mac-
rophages were laden with AcLDL (48 hours; 50 g/mL) in the
presence of [3H]cholesterol (2 Ci/mL) and the accumulation of
label was assessed (A). Subsequently, cholesterol efflux with
and without HDL (50 g/mL) was determined over a period of
10 hours (B). After 4 hours of incubation ABCA1-mediated cho-
lesterol efflux from lipid-laden J774 macrophages (C) and SR-
BI–mediated cholesterol efflux from lipid-laden Fu5AH cells (D)
was assessed in the absence (control) or presence of apoAI (10
g/mL) or HDL (50 g/mL), or a plasma pool from 10 CETP.E3L
(1%), or E3L (1%) mice fed the Western type diet for 19 weeks.
*P0.05.
Westerterp et al CETP Aggravates Atherosclerosis in APOE*3-Leiden Mice 2555
 at SWETS SUBSCRIPTION SERVICE on August 14, 2015http://atvb.ahajournals.org/Downloaded from 
sion led to a net shift of cholesterol from HDL toward VLDL,
resulting in 2-fold increased VLDL cholesterol plasma levels
and 2-fold decreased HDL cholesterol levels. This led to a
reduced capacity of the plasma to induce SR-BI–mediated
cholesterol efflux, yet did not affect ABCA1-mediated cho-
lesterol efflux. Furthermore, CETP expression resulted in
much more advanced atherosclerotic lesions and a 7.0-fold
increase in atherosclerotic lesion area in E3L mice.
CETP permits bidirectional transfer between apoB-
containing lipoproteins and HDL, resulting in net flux of TG
from VLDL and LDL to HDL, and net flux of cholesterol
from HDL to VLDL and LDL.33 Because apoE3-Leiden has
a reduced affinity for the hepatic LDLr as compared with
wild-type apoE, E3L mice have increased VLDL cholester-
ol.19 CETP expression in E3L mice caused an additional
increase in VLDL cholesterol, probably by increasing the net
cholesterol flux from HDL to VLDL,33 thereby further
impeding VLDL clearance. Furthermore, CETP expression in
E3L mice reduced HDL levels. Next to a 25% decrease in
HDL-2 and HDL-3, as reflected by a decrease in both apoAI
and cholesterol in these HDL subpopulations, CETP expres-
sion resulted in disappearance of apoAI-deficient and apoE-
rich HDL-1, which is present in E3L mice.19 Likewise, CETP
expression has been shown to eliminate HDL-1 that accumu-
lates in LCAT transgenic mice.12 Apparently, HDL-1 is a
preferential substrate for CETP. This hypothesis is corrobo-
rated by the finding that HDL-1 accumulates in CETP-
deficient humans.8,9 The CETP-induced reduction in HDL
may be explained by: (1) reduced lipidation of HDL apoli-
poproteins, resulting in enhanced renal clearance of lipid-
poor apoAI; (2) enrichment of HDL in TG, resulting in a
more efficient hepatic lipase (HL)-mediated HDL catabo-
lism;34 and/or (3) direct uptake of HDL–CE by liver-
associated CETP, as has recently been proposed by Gauthier
et al.4
On a chow diet, the CETP concentration in CETP.E3L
mice was 3-fold higher than in human plasma.30 On the
Western-type diet, plasma CETP activity and mass were
4-fold and 12-fold increased, respectively, as compared with
the chow diet. This indicates that inactive CETP accumulated
on HDL on a Western-type via an as yet unidentified
mechanism. The observation that a cholesterol-rich diet leads
to CETP accumulation in plasma is consistent with previous
observations in apoE-deficient and LDLr-deficient mice.35
Also in humans, a positive correlation between plasma lipid
levels and plasma CETP concentration was found.30 In
addition, CETP activity was found to correlate with CETP
concentration in both normolipidemic humans and hyperlip-
idemic humans.30 In line with hyperlipidemic versus normo-
lipidemic CETP.E3L mice, also a higher level of inactive
CETP was found in hyperlipidemic versus normolipidemic
humans.30 Regulation of CETP expression involves an liver X
receptor-response element36 that is present in the natural
flanking regions of the human CETP transgenic mouse strain
that we used for crossbreeding with E3L mice.11 Most likely,
the cholesterol diet-induced hypercholesterolemia thus results
in increased hepatic cholesterol as well as oxysterols, the
natural ligands for the liver X receptor,37 thereby increasing
CETP expression, as reflected by increased plasma CETP
levels. A similar mechanism may explain the positive corre-
lation between plasma cholesterol and CETP levels in
humans.
In previous studies in E3L mice, VLDL cholesterol has
been found to correlate well with atherosclerotic lesion area,
most probably by initiating atherosclerosis on entry of VLDL
into the vascular wall.19 Specifically, feeding E3L mice a
high-cholesterol diet as compared with a low-cholesterol diet
resulted in 2-fold increased VLDL cholesterol levels and a
2-fold increased atherosclerotic lesion area.38 We now ob-
served that a similar 2-fold increase in VLDL cholesterol
levels as induced by the introduction of CETP in E3L mice
caused even a 7.0-fold increase in atherosclerotic lesion area.
This cannot simply be explained by a CETP-mediated in-
crease in VLDL, and suggests that other mechanisms are
involved in this process, which may include a local effect of
CETP on lipid accumulation in macrophages and/or the
observed reduction in HDL.
We found that the expression of CETP in macrophages did
not affect AcLDL-induced foam cell formation or cholesterol
efflux to human HDL. This is in contrast with findings in a
monkey fibroblast cell line (COS-7), which showed that
transfection with a CETP construct induces cholesterol ef-
flux.39 This seeming discrepancy may be caused by a differ-
Figure 3. Effect of CETP on the development of atherosclerotic
lesion severity and area in the aortic root. E3L (white symbols)
(n12) and CETP.E3L (black symbols) (n11) mice were eutha-
nized after 19 weeks of Western type diet (containing 0.25%
cholesterol) feeding, and hearts were isolated, fixed, dehy-
drated, and embedded in paraffin. Hearts were cross-sectioned
(5 m) throughout the entire aortic root, and stained with
hematoxylin-phloxine-saffron (HPS). Representative pictures are
shown (A). Four sections per mouse with 40 m intervals were
typed and categorized according to lesion severity (B) and the
extent of atherosclerosis was quantified (C). Each data point
represents the mean lesion area per mouse (C). ****P0.0001.
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ence in CETP expression. However, it is thus unlikely that
CETP expression in macrophages contributed to the observed
increased atherosclerosis development by affecting the cellu-
lar lipid homeostasis.
Alternatively, CETP may affect RCT by reducing plasma
levels of HDL, which is crucially involved in RCT. The first
step in this process is cholesterol efflux from the macrophage,
as mediated by ABCA1 and SR-BI. The shift of plasma
cholesterol from HDL to VLDL as induced by CETP expres-
sion did not affect ABCA1-mediated cholesterol efflux yet
reduced SR-BI-mediated efflux. It has been shown that small
lipid-poor HDL has the strongest association with ABCA1-
mediated cholesterol efflux, even in the presence of other
HDL subpopulations.40 Regarding the HDL cholesterol dis-
tribution, CETP.E3L mice mostly express small HDL, prob-
ably as a consequence of HDL remodeling by CETP. Appar-
ently, the difference in levels of small HDL particles between
plasma from CETP.E3L and E3L mice is not sufficient to
affect ABCA1-mediated cholesterol efflux. The observation
that CETP expression does not compromise ABCA1-
mediated cholesterol efflux to HDL is in agreement with data
from a previous study in rabbits treated with a
CETP-inhibitor.41
Whereas CETP expression did not affect ABCA1-
mediated efflux, it decreased the SR-BI-mediated cholesterol
efflux. As different HDL subpopulations contribute equally to
SR-BI–mediated cholesterol efflux,40 and total HDL levels
were lower in the plasma of CETP.E3L mice (especially
HDL-1), this can thus easily explain the reduced SR-BI
efflux. Nevertheless, ABCA1 and SR-BI do not constitute all
the pathways that mediate cholesterol efflux from macro-
phages.42 ABCG1 also mediates cholesterol efflux, and has
been shown to be highly functional in inducing cholesterol
efflux to HDL from CETP-deficient subjects.43 Because
ABCG1 and SR-BI both use HDL as cholesterol acceptor,40,43
an additional effect of the CETP-induced lipoprotein shift on
ABCG1-mediated efflux cannot be ruled out. Finally, it may
be postulated that VLDL contributes to cholesterol efflux,
similarly as has been documented for LDL.44 However, even
if VLDL contributes to cholesterol efflux, plasma from
CETP.E3L mice showed a decreased SR-BI–mediated cho-
lesterol efflux despite higher VLDL levels.
It remains to be elucidated whether CETP-induced reduced
HDL will be rate-limiting for integrated RCT in vivo, ie, the
transport of cholesterol from macrophages to the liver,
leading to fecal secretion. A recent study has demonstrated
that CETP inhibition in rabbits does not affect the clearance
of HDL cholesterol,45 and we have obtained initial data that
CETP expression does not affect HDL–CE turnover in E3L
mice (unpublished). However, our observations that CETP
expression in E3L mice reduced cholesterol efflux in vitro,
and strongly increased atherosclerosis in vivo, suggest that
CETP reduced RCT in E3L mice.
Collectively, we have now shown that CETP is a clear
pro-atherogenic factor in E3L mice. Because CETP also
appeared pro-atherogenic in apoe/ and ldlr/ mice,14
CETP thus seems to be consistently pro-atherogenic in the
context of reduced hepatic uptake of apoB-containing li-
poproteins, at least partly by further increasing the levels of
cholesterol-rich VLDL. In contrast, CETP is anti-atherogenic
in APOC3 and LCAT transgenic mice.12,13 APOC3 mice
accumulate particularly TG-rich VLDL as a result of LPL
inhibition, enabling a massive flux of TG from apoB-
containing lipoproteins to HDL,46 which may result in an
accelerated clearance of TG-rich HDL particles via HL. As a
consequence, smaller, cholesterol-poor HDL particles are
formed,46 which may have higher anti-atherogenic potential
by more efficiently inducing cholesterol efflux. LCAT trans-
genic mice accumulate apoE-rich HDL-1, that is not effi-
ciently cleared by the liver and therefore are more susceptible
to atherosclerosis.12 CETP expression in LCAT mice provides
an extra pathway of delivering HDL cholesterol to the liver,
resulting in normalization of the HDL particle size12 and
presumably increasing its cholesterol-accepting potency.
The E3L mouse model has been proven very suitable for
testing hypolipidemic drugs that affect VLDL/LDL metabo-
lism.19,47 Atorvastatin,47 rosuvastatin,48 and gemfibrozil49 re-
duced the levels of the VLDL/LDL in E3L mice comparable
to humans. As the introduction of CETP results in the
potential to modulate HDL cholesterol levels in addition to
VLDL cholesterol levels, we anticipate that the CETP.E3L
mouse will be suitable for the preclinical evaluation of
HDL-increasing therapies (including CETP inhibitors), which
constitute a novel target in the treatment of cardiovascular
disease.
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Online figure I. Effect of CETP on cholesterol levels in E3L mice fed a Western-
type diet containing 0.25% cholesterol. E3L and CETP·E3L mice were fed a 
Western-type diet containing 0.25% cholesterol from 8 weeks of age (t=0). Fasted 
plasma was collected from E3L (white symbols) and CETP·E3L mice (black symbols) 
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